EU Committee Backs Olumiant for Adolescent Alopecia Areata, Positive for Incyte
INCY sits 85% above its 52-week low of $53.56.
Summary
Incyte and Eli Lilly's Olumiant has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for expanded approval in adolescents aged 12 and older with severe alopecia areata. This significant regulatory milestone, which follows existing approval for adults, broadens the potential market for Olumiant in Europe. The CHMP backing is a strong indicator for full European Commission approval, which is typically granted within one to two months. This development is a material positive for Incyte, given Olumiant's importance to its product portfolio, and also benefits partner Eli Lilly.
At the time of this announcement, INCY was trading at $98.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9B. The 52-week trading range was $53.56 to $112.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.